Sage shares get a bump from a snapshot of new PhII depression data

Steve Kanes, Sage

Sage Therapeutics $SAGE has had a lot of success posting interim snapshots on the data it’s been gathering for its pipeline drugs. And the biotech scored another surge in its share price today with a sliver of data from the first stage of its Phase II study of its depression drug SAGE-217.

Looking at 13 patients – a tiny group for a disease like depression – investigators say that 11 of them demonstrated a minimum 50% reduction in disease scores. And 8 of them achieved remission.

This was an open-label stretch of the study, with no placebo control arm. Placebo effects in these studies have proven to be a tough hurdle for developers to clear, scuttling a large number of depression drugs in the past.

Investors were willing to give the preliminary results a thumbs up, though. The biotech’s stock jumped 12% on the latest update from Sage.

“Our novel, orally-administered molecule, SAGE-217, was designed to reproduce the important GABA-related pharmacology of our intravenous agent SAGE-547, and is an example of our translational approach to drug development. The positive results from this clinical trial, along with the outcomes observed with SAGE-547 in postpartum depression, further validate studying this mechanism as a potential broad therapy for the treatment of mood disorders,” said Steve Kanes, the chief medical officer of Sage. “SAGE-217 has the potential to be a rapid-acting, once-daily oral therapy for MDD, with a novel mechanism of action.”

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->